65,437 trials
Carotid Artery Stenosis
Primary: Percentage of Patients Experiencing Major Adverse Events (MAE) — 6.9 percentage of participants
Intervertebral Disk Displacement · Disk Prolapse
Primary: Mean VAS Pain (Visual Analogue Scale)at Rest (0-100 mm) — 11.7; 22.5 Units on a scale
Healthy Volunteers
Primary: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] — 307.225; 324.324; 330.411 hr*ng/mL
Alpha 1-Antitrypsin Deficiency
Primary: Area Under the Curve/Dose — 0.0822; 0.0920 days*kg/mL
Non-diabetic Nephropathy With Hypertension
Primary: The Change in Urinary Protein/Creatinine Ratio From Baseline to 28 Weeks — 794.0; 639.9; 819.0 mg/g
Esophageal Cancer · Gastric Cancer
Primary: Pathologic Complete Response Rate — 15.4; 16.7 percentage of participants
Pancreatic Cancer
Primary: Proportion of Patients With Objective Response Evaluated by RECIST (Solid Tumor Response Criteria) — 0.045; 0.07 Proportion of participants
Parkinson Disease
Primary: Percentage of Participants With Adverse Events, Adverse Drug Reactions, and Serious Adverse Events — 21.7; 19.2; 2.5 percentage of participants
Puberty, Precocious · McCune-Albright Syndrome
Primary: Change in Frequency of Annualized Days of Vaginal Bleeding on Treatment Compared to Baseline — -3.6 Days per year
Non-Small-Cell Lung Cancer
Primary: Progression-Free Survival — 9.0; 11.3 Months
Respiratory Syncytial Virus Infection · Premature Birth · Bronchopulmonary Dysplasia
Primary: Frequency of Adverse Events — 41 participants
Metastatic Solid Tumor
Primary: Maximum Tolerated Dosage (MTD) of Intravenous Topotecan When Given in Combination With Oral Erlotinib — 1.0 mg/m^2
Infection
Primary: Percentage of Participants With Clinical and Microbiological Cure: All Participants — 33.8 percentage of participants
Pneumococcal Vaccines
Primary: Geometric Mean Concentration (GMC) of Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibodies 1 Month After the Toddler Dose — 5.27; 5.06; 9.63; 8.75 mcg/mL
Non-Small Cell Lung Cancer
Primary: Investigator-assessed Objective Progression-free Survival (PFS) — 4.11; 2.83 months — p=0.00006